Stocks › JAZZ
Jazz Pharmaceuticals Plc (JAZZ) stock analysis
WEAK BUY 27% confidence · analysed Nov 3, 2026
On Nov 3, 2026, our model rated Jazz Pharmaceuticals Plc (JAZZ) WEAK BUY with 27% confidence at a price of $229.74. That means the signals lean positive, but they are mixed, so conviction is low.
Technical picture
The 14-day RSI is 67, showing healthy upward momentum without being stretched.
MACD is above its signal line, a sign that short-term momentum is turning up.
The price has slipped below its 50-day moving average but is still above the 200-day: a pullback inside a longer-term uptrend.
Volume is 1.9x its 20-day average, so the latest move has real participation behind it.
Trend structure and money flow
Market structure shows a bullish break of structure (BOS): price broke a recent swing high in the direction of the trend, which usually signals trend continuation.
The most recent swing high is $182.99 and the swing low is $156.95; traders often treat these as resistance and support.
Fundamentals
The PEG ratio is 0.96, which looks cheap relative to its expected growth.
The company reports a profit margin of 20.4% and revenue growth of +15.5%.
In its latest quarter it earned $-3.88 per share, which missed the $-2.38 analysts expected, with revenue +15.5% year over year.
Wall Street's average rating is 1.5 on a 1 (strong buy) to 5 (sell) scale, roughly a "strong buy", with an average price target of $295.77.
The next earnings report is expected around Feb 23, 2027; prices often move sharply around earnings.
Trade plan from the model
The model's long / bullish plan uses an entry near $229.74, a target of $243.72 (+6.1%) and a stop-loss at $215.82 (-6.1%).
That is a reward-to-risk ratio of about 1.0 to 1: the potential gain is not much bigger than the loss, so the setup is marginal.
The plan has a time limit: reassess by Nov 13, 2026 whatever the price does.
The model's one-paragraph read
Leans BUY — composite score +0.27 (WEAK BUY). Technicals: RSI 66.72, MACD bullish, price below SMA50. Fundamentals: PEG 0.96, margin 20.4%, revenue growth 15.5%. Financial results: YoY revenue +15.5%, last EPS surprise -63.0%, next earnings 2027-02-23. Smart Money Concepts: BOS bullish (trend continuation). FinGPT news read: positive. Suggested levels: entry $229.74, target $243.72, stop-loss $215.82, exit by 2026-11-13 (10-calendar-day max hold (time-stop; reassess by this date regardless of P&L)).
Past ratings for JAZZ
| Date | Verdict | Confidence | Price | Move since | |
|---|---|---|---|---|---|
| Nov 3, 2026 | WEAK BUY | 27% | $229.74 | — |
"Move since" compares each call's price with the latest analysed price.
Recent news on JAZZ
- Nov 3, 2026: Jazz Pharmaceuticals to Participate in Upcoming Investor Conferences (PR Newswire)
- Nov 3, 2026: 4 Biotech Stocks Seeing Unusual Options Volume Today (Schaeffer's Research)
- Nov 2, 2026: Jazz: Q3 Earnings Snapshot (Associated Press)
- Nov 2, 2026: Jazz Pharmaceuticals Beats As Revenue Guidance Rises Again, But Slowing Growth And An Actio Charge Leave The Stock At A Crossroads (Earnings Whispers)
- Nov 2, 2026: Jazz Pharmaceuticals Announces Third Quarter 2026 Financial Results (PR Newswire)
- Nov 2, 2026: Jazz Pharmaceuticals to Highlight Neuro-Oncology Clinical Research at SNO 2026 (PR Newswire)
Frequently asked questions
Is JAZZ a buy right now?
As of Nov 3, 2026, our automated model rates Jazz Pharmaceuticals Plc (JAZZ) WEAK BUY with 27% confidence: the signals lean positive, but they are mixed, so conviction is low. This is a model output for education, not personal investment advice.
What is the price target for JAZZ?
The model's most recent plan targets $243.72 with a stop-loss at $215.82, from an entry near $229.74.
When does Jazz Pharmaceuticals Plc report earnings next?
The next earnings report is expected around Feb 23, 2027.
What does a WEAK BUY rating mean?
A WEAK BUY rating means the signals lean positive, but they are mixed, so conviction is low.
For information and education only. Not investment advice. Ratings are produced by an automated model, can be wrong, and may be out of date. Do your own research; you can lose money investing. The site's author may hold positions in stocks discussed here.